SG11201400232WA - Heterocyclylamines as pi3k inhibitors - Google Patents

Heterocyclylamines as pi3k inhibitors

Info

Publication number
SG11201400232WA
SG11201400232WA SG11201400232WA SG11201400232WA SG11201400232WA SG 11201400232W A SG11201400232W A SG 11201400232WA SG 11201400232W A SG11201400232W A SG 11201400232WA SG 11201400232W A SG11201400232W A SG 11201400232WA SG 11201400232W A SG11201400232W A SG 11201400232WA
Authority
SG
Singapore
Prior art keywords
heterocyclylamines
pi3k inhibitors
pi3k
inhibitors
Prior art date
Application number
SG11201400232WA
Inventor
Yun-Long Li
Wenqing Yao
Andrew P Combs
Eddy W Yue
Song Mei
Wenyu Zhu
Joseph Glenn
Thomas P Maduskuie Jr
Richard B Sparks
Brent Douty
Chunhong He
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of SG11201400232WA publication Critical patent/SG11201400232WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201400232WA 2011-09-02 2012-08-31 Heterocyclylamines as pi3k inhibitors SG11201400232WA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161530866P 2011-09-02 2011-09-02
US201261594882P 2012-02-03 2012-02-03
US201261677445P 2012-07-30 2012-07-30
PCT/US2012/053398 WO2013033569A1 (en) 2011-09-02 2012-08-31 Heterocyclylamines as pi3k inhibitors

Publications (1)

Publication Number Publication Date
SG11201400232WA true SG11201400232WA (en) 2014-03-28

Family

ID=47071429

Family Applications (3)

Application Number Title Priority Date Filing Date
SG11201400232WA SG11201400232WA (en) 2011-09-02 2012-08-31 Heterocyclylamines as pi3k inhibitors
SG10201601589QA SG10201601589QA (en) 2011-09-02 2012-08-31 Heterocyclylamines as pi3k inhibitors
SG10201912484RA SG10201912484RA (en) 2011-09-02 2012-08-31 Heterocyclylamines as pi3k inhibitors

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10201601589QA SG10201601589QA (en) 2011-09-02 2012-08-31 Heterocyclylamines as pi3k inhibitors
SG10201912484RA SG10201912484RA (en) 2011-09-02 2012-08-31 Heterocyclylamines as pi3k inhibitors

Country Status (37)

Country Link
US (9) US9199982B2 (en)
EP (4) EP2751109B1 (en)
JP (8) JP6067709B2 (en)
KR (7) KR102507287B1 (en)
CN (1) CN106986867B (en)
AR (1) AR087760A1 (en)
AU (5) AU2012301721B2 (en)
BR (2) BR122019020716B1 (en)
CA (1) CA2846652C (en)
CL (1) CL2014000517A1 (en)
CO (1) CO6910199A2 (en)
CR (2) CR20180293A (en)
CY (3) CY1118679T1 (en)
DK (3) DK2751109T3 (en)
EA (2) EA033646B1 (en)
EC (1) ECSP14013274A (en)
ES (3) ES2722524T3 (en)
HK (1) HK1199644A1 (en)
HR (3) HRP20170285T1 (en)
HU (3) HUE030869T2 (en)
IL (6) IL299533A (en)
LT (3) LT2751109T (en)
ME (2) ME03397B (en)
MX (2) MX2020004502A (en)
MY (1) MY179332A (en)
NZ (1) NZ769326A (en)
PE (2) PE20181272A1 (en)
PH (2) PH12017501766B1 (en)
PL (3) PL3196202T3 (en)
PT (3) PT2751109T (en)
RS (3) RS61761B1 (en)
SG (3) SG11201400232WA (en)
SI (3) SI3196202T1 (en)
SM (1) SMT201700111B (en)
TW (6) TWI717002B (en)
WO (1) WO2013033569A1 (en)
ZA (1) ZA201904877B (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2448938T3 (en) 2009-06-29 2014-11-28 Incyte Holdings Corp Pyrimidinones as pi3k inhibitors
US8759359B2 (en) * 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
WO2011075630A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors
WO2011130342A1 (en) 2010-04-14 2011-10-20 Incyte Corporation FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
JP5961187B2 (en) 2010-12-20 2016-08-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ N- (1- (substituted phenyl) ethyl) -9H-purin-6-amine as a PI3K inhibitor
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
HUE030869T2 (en) 2011-09-02 2017-06-28 Incyte Holdings Corp Heterocyclylamines as pi3k inhibitors
AR090548A1 (en) 2012-04-02 2014-11-19 Incyte Corp BICYCLIC AZAHETEROCICLOBENCILAMINS AS PI3K INHIBITORS
CA2875986C (en) 2012-06-04 2020-06-09 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
JP6434416B2 (en) 2012-11-08 2018-12-05 ライゼン・ファーマシューティカルズ・エスアー Pharmaceutical composition comprising a PDE4 inhibitor and a PI3δ inhibitor or a dual PI3δ-γ kinase inhibitor
JP6437452B2 (en) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
MX2015009057A (en) 2013-01-15 2015-10-05 Incyte Corp Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors.
TWI736135B (en) 2013-03-01 2021-08-11 美商英塞特控股公司 USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS
TW201605866A (en) 2013-08-23 2016-02-16 英塞特公司 Furo- and thieno-pyridine carboxamide compounds useful as PIM kinase inhibitors
WO2015117147A1 (en) 2014-02-03 2015-08-06 Quadriga Biosciences, Inc. Beta-substituted beta-amino acids and analogs as chemotherapeutic agents
WO2015117146A1 (en) 2014-02-03 2015-08-06 Quadriga Biosciences, Inc. Beta-substituted gamma-amino acids and analogs as chemotherapeutic agents
UA119767C2 (en) 2014-04-08 2019-08-12 Інсайт Корпорейшн Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
AU2016222556B2 (en) * 2015-02-27 2020-08-27 Incyte Holdings Corporation Salts of Pl3K inhibitor and processes for their preparation
MD3265084T2 (en) 2015-03-03 2024-05-31 Pharmacyclics Llc Pharmaceutical formulations of Bruton's tyrosine kinase inhibtor
EP3269367B1 (en) * 2015-03-11 2020-10-07 Riken Therapeutic agent for intractable leukemia
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183071A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Hetero-tricyclic compounds and their use for the treatment of cancer
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
KR20180035894A (en) 2015-08-03 2018-04-06 콰드리가 바이오사이언시스 인코포레이티드 Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereof
US9708333B2 (en) 2015-08-12 2017-07-18 Incyte Corporation Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors
WO2017035366A1 (en) 2015-08-26 2017-03-02 Incyte Corporation Pyrrolopyrimidine derivatives as tam inhibitors
AR105967A1 (en) 2015-09-09 2017-11-29 Incyte Corp SALTS OF A PIM QUINASA INHIBITOR
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
AR106595A1 (en) 2015-11-06 2018-01-31 Incyte Corp HETEROCYCLIC COMPOUNDS AS PI3K-g INHIBITORS
US20170190689A1 (en) 2016-01-05 2017-07-06 Incyte Corporation Pyridine and pyridimine compounds as pi3k-gamma inhibitors
PE20190175A1 (en) 2016-03-28 2019-02-01 Incyte Corp PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS
TW201803871A (en) 2016-06-24 2018-02-01 英塞特公司 Heterocyclic compounds as PI3K-[gamma] inhibitors
KR20200088308A (en) 2017-09-27 2020-07-22 인사이트 코포레이션 Salts of pyrrolotriazine derivatives useful as TAM inhibitors
JP7244504B2 (en) 2017-10-18 2023-03-22 インサイト・コーポレイション Fused Imidazole Derivatives Substituted with Tertiary Hydroxy Groups as PI3K-γ Inhibitors
AR113922A1 (en) 2017-12-08 2020-07-01 Incyte Corp LOW DOSE COMBINATION THERAPY FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS
PT3762368T (en) 2018-03-08 2022-05-06 Incyte Corp Aminopyrazine diol compounds as pi3k-y inhibitors
WO2019232188A1 (en) 2018-06-01 2019-12-05 Incyte Corporation Dosing regimen for the treatment of pi3k related disorders
AR117600A1 (en) 2018-06-29 2021-08-18 Incyte Corp FORMULATIONS OF AN AXL / MER INHIBITOR
PT3847175T (en) 2018-09-05 2024-04-16 Incyte Corp Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor
WO2020102216A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Substituted heterocyclic derivatives as pi3k inhibitors
US11161838B2 (en) 2018-11-13 2021-11-02 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
WO2020102198A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
TW202114681A (en) 2019-07-02 2021-04-16 美商ｅＦＦＥＣＴＯＲ醫療公司 Translation inhibitors and uses thereof
US20210253582A1 (en) * 2020-02-06 2021-08-19 Incyte Corporation Salts and solid forms and processes of preparing a pi3k inhibitor
US20220241411A1 (en) 2020-11-30 2022-08-04 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
WO2022115120A1 (en) 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
AR127966A1 (en) 2021-12-16 2024-03-13 Incyte Corp TOPICAL FORMULATIONS OF PI3K-DELTA INHIBITORS
US11958832B1 (en) 2023-10-12 2024-04-16 King Faisal University 2-alkoxy[4,3:6,3-terpyridine]-3-carbonitriles as antimicrobial compounds

Family Cites Families (293)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3169967A (en) 1957-11-14 1965-02-16 Ciba Geigy Corp Methyl o-lower alkanoyl-reserpates
US3037980A (en) 1955-08-18 1962-06-05 Burroughs Wellcome Co Pyrrolopyrimidine vasodilators and method of making them
DE1770420U (en) 1958-02-27 1958-07-17 Tara Union G M B H FLOWER POT MADE OF PLASTIC.
US3506643A (en) 1966-12-09 1970-04-14 Max Thiel N**6-aralkyl-adenosine derivatives
DE2139107A1 (en) 1971-08-04 1973-02-15 Merck Patent Gmbh N(6)-subst adenosine derivs - with coronary circulatory etc activity
US3814251A (en) 1972-08-09 1974-06-04 Sperry Rand Corp Power transmission
US3962443A (en) 1972-08-14 1976-06-08 Dainippon Pharmaceutical Co., Ltd. Antibacterial pharmaceutical compositions and processes for preparation thereof
DE2248232A1 (en) 1972-10-02 1974-04-11 Basf Ag 4-THIOPYRIMIDO SQUARE BRACKET ON 4.5 D SQUARE BRACKET FOR PYRIMIDINE
AR204003A1 (en) 1973-04-03 1975-11-12 Dainippon Pharmaceutical Co PROCEDURE FOR PREPARING COMPOUNDS DERIVED FROM 2- (1-PIPERAZINYL) -5-OXOPYRIDE- (2,3-D) PYRIMIDINE-6-CARBOXYL ACID AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
US3936454A (en) 1973-08-14 1976-02-03 Warner-Lambert Company 5-Amino-4-chloro-6-(substituted amino)-pyrimidines
US3862189A (en) 1973-08-14 1975-01-21 Warner Lambert Co Aralkyl-substituted purines and pyrimidines as antianginal bronchodilator agents
DK3375A (en) 1974-01-25 1975-09-15 Ciba Geigy Ag
JPS587626B2 (en) 1974-02-13 1983-02-10 大日本製薬株式会社 Naphthyridine and quinoline
JPS50111080U (en) 1974-02-21 1975-09-10
JPS5625234Y2 (en) 1976-01-17 1981-06-15
JPS5359663A (en) 1976-11-09 1978-05-29 Sumitomo Chem Co Ltd 2-halogeno methyl indole derivatives and process for praparation of the same
JPS52106897A (en) 1977-01-10 1977-09-07 Dainippon Pharmaceut Co Ltd Synthesis of piperazine derivatives
JPS5392767A (en) 1977-01-27 1978-08-15 Sumitomo Chem Co Ltd Preparation of 2-phthalimidomethylindole derivatives
JPS5625234A (en) 1979-08-02 1981-03-11 Hitachi Denshi Ltd Dropout display system
JPS56123981U (en) 1980-02-20 1981-09-21
JPS56123981A (en) 1981-02-23 1981-09-29 Dainippon Pharmaceut Co Ltd Preparation of 1,4-disubstituted piperazine
JPS5883698A (en) 1981-11-13 1983-05-19 Takeda Chem Ind Ltd Quinone compound and its preparation
JPS5883698U (en) 1981-11-27 1983-06-06 石川島播磨重工業株式会社 Heat exchanger
JPS58162949A (en) 1982-03-20 1983-09-27 Konishiroku Photo Ind Co Ltd Color photographic sensitive silver halide material
JPS60140373U (en) 1984-02-28 1985-09-17 東洋ハ−ネス株式会社 Wire harness earth structure
JPS6190153A (en) 1984-10-09 1986-05-08 Fuji Photo Film Co Ltd Treatment of silver halide photosensitive material
JPS62103640A (en) 1985-07-18 1987-05-14 Fuji Photo Film Co Ltd Silver halide color photographic sensitive material
JPS62103640U (en) 1985-12-18 1987-07-02
JPH07119970B2 (en) 1986-04-18 1995-12-20 富士写真フイルム株式会社 Image forming method
JPS6310746A (en) 1986-07-01 1988-01-18 Tanabe Seiyaku Co Ltd Naphthalene derivative
CA1324609C (en) 1986-07-30 1993-11-23 Eastman Kodak Company Photographic element and process
US4861701A (en) 1987-10-05 1989-08-29 Eastman Kodak Company Photographic element and process comprising a compound which comprises two timing groups in sequence
AT388372B (en) 1987-10-08 1989-06-12 Tanabe Seiyaku Co Novel naphthalene derivatives and pharmaceuticals containing them
JPH01250316A (en) 1987-12-28 1989-10-05 Tanabe Seiyaku Co Ltd Cholesterol-lowering agent
WO1989008113A1 (en) 1988-03-02 1989-09-08 Yoshitomi Pharmaceutical Industries, Ltd. 3,4-DIHYDROTHIENO[2,3-d]PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL APPLICATION THEREOF
US5208250A (en) 1988-05-25 1993-05-04 Warner-Lambert Company Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents
JPH07107055B1 (en) 1990-04-25 1995-11-15
SU1712359A1 (en) 1990-05-07 1992-02-15 Уфимский Нефтяной Институт 8'-hydroxyquinoline-7-carboxylic acid 8-hydroxyquinoline ester hydrochloride as a bactericidal agent for inhibition of sulfate-reducing bacteria and cultures pseudomonas and arthrobacter
DE69129389T2 (en) 1990-06-28 1998-10-08 Fuji Photo Film Co Ltd Silver halide photographic materials
EP0481614A1 (en) 1990-10-01 1992-04-22 Merck & Co. Inc. Substituted pyridopyrimidinones and related heterocycles as angiotensin II antagonists
JPH04190232A (en) 1990-11-26 1992-07-08 Fuji Photo Film Co Ltd Silver halide photosensitive material for color photograph
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
IL101860A0 (en) 1991-05-31 1992-12-30 Ici Plc Heterocyclic derivatives
JP3108483B2 (en) 1991-09-30 2000-11-13 日清製粉株式会社 Indole derivatives and anti-ulcer drugs containing the same as active ingredients
HUT64064A (en) 1992-02-13 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing puyrido/1,2-a/pyrimidine derivatives and pharmaceutical compositions comprising same as active ingredient
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
AU3933493A (en) 1992-04-24 1993-11-29 E.I. Du Pont De Nemours And Company Arthropodicidal and fungicidal aminopyrimidines
TW229140B (en) 1992-06-05 1994-09-01 Shell Internat Res Schappej B V
FR2714907B1 (en) 1994-01-07 1996-03-29 Union Pharma Scient Appl New adenosine derivatives, their preparation processes, pharmaceutical compositions containing them.
US6342501B1 (en) 1994-02-25 2002-01-29 The Regents Of The University Of Michigan Pyrrolo[2,3-d] pyrimidines as antiviral agents
JPH0987282A (en) 1995-09-21 1997-03-31 Kyowa Hakko Kogyo Co Ltd Thiazole derivative
JPH09176162A (en) 1995-12-22 1997-07-08 Toubishi Yakuhin Kogyo Kk Thiazolidinedione derivative, its production and medicinal composition containing the same
JPH09176116A (en) 1995-12-27 1997-07-08 Toray Ind Inc Heterocyclic derivative and its pharmaceutical use
JPH1025294A (en) 1996-03-26 1998-01-27 Akira Matsuda Condensed heterocyclic derivative, its production and malignant tumor therapeutic agent containing the same
WO1997048697A1 (en) 1996-06-19 1997-12-24 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
AU698419B2 (en) 1996-07-03 1998-10-29 Dainippon Sumitomo Pharma Co., Ltd. A novel purine derivative
US5866702A (en) 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
JPH10231297A (en) 1997-02-20 1998-09-02 Japan Energy Corp New adenine-1-noxide derivative, and use of the same as medicine
CA2309350C (en) 1997-11-12 2007-04-03 Mitsubishi Chemical Corporation Purine derivatives and medicaments comprising the same as active ingredient
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
EE200000522A (en) 1998-02-25 2002-02-15 Genetics Institute, Inc. Phospholipase A2 Enzyme Inhibitor, a Pharmaceutical Composition Containing It and a Method for Inhibiting the Phospholipase Enzyme Activity
AU2782699A (en) 1998-02-25 1999-09-15 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6479487B1 (en) 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
CZ20003960A3 (en) 1998-05-04 2002-04-17 Zentaris Ag Indole derivatives and their use for treating malignant and other diseases induced by pathological proliferation of cells
JP4549534B2 (en) 1998-05-26 2010-09-22 中外製薬株式会社 Indole derivatives and mono- or diazaindole derivatives having a heterocyclic ring
JP3997651B2 (en) 1998-06-24 2007-10-24 コニカミノルタホールディングス株式会社 Novel dye, image recording material, thermal transfer material and ink jet recording liquid
DE69942097D1 (en) 1998-08-11 2010-04-15 Novartis Ag ISOCHINOLINE DERIVATIVES WITH ANGIOGENESIS-HEMMENDER EFFECT
AU4963999A (en) 1998-08-25 2000-03-14 Uab Research Foundation, The Inhibitors of bacterial nad synthetase
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
CN1353713A (en) 1999-02-01 2002-06-12 Cv治疗公司 Purine inhibitors of cyclin dependent kinase 2 and IK B-alpha
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
JP2000281654A (en) 1999-03-26 2000-10-10 Tanabe Seiyaku Co Ltd Isoquinoline dertivative
DE19932571A1 (en) 1999-07-13 2001-01-18 Clariant Gmbh Process for the preparation of biarylene using palladophosphacyclobutane catalysis
JP2001151771A (en) 1999-09-10 2001-06-05 Kyowa Hakko Kogyo Co Ltd Nitrogen-containing aromatic heterocyclic derivative
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US6436965B1 (en) 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
EP1138328A1 (en) 2000-03-29 2001-10-04 Eli Lilly And Company Limited Naphthalene derivatives as CNS drugs
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
PL202623B1 (en) 2000-06-28 2009-07-31 Smithkline Beecham Plc Wet milling process
CN1331340A (en) 2000-06-30 2002-01-16 上海博德基因开发有限公司 Polypeptide-human topoisomerase 12.1 and polynucleotide for coding it
ES2261437T3 (en) 2000-07-05 2006-11-16 Astellas Pharma Inc. DERIVATIVES OF PROPANE-1,3-DIONA.
FR2814073B1 (en) 2000-09-21 2005-06-24 Yang Ji Chemical Company Ltd ANTIFUNGAL AND / OR ANTIPARASITIC PHARMACEUTICAL COMPOSITION AND NOVEL INDOLE DERIVATIVES AS ACTIVE INGREDIENTS OF SUCH A COMPOSITION
DOP2002000334A (en) 2001-02-14 2002-08-30 Warner Lambert Co BICYCLE PYRIMIDINES AS MATRIX METALOPROTEINASE INHIBITORS
SE0100568D0 (en) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
EP2033952B1 (en) 2001-03-01 2012-08-29 Shionogi&Co., Ltd. Nitrogen-containing Heteroaryl compounds having HIV Integrase Inhibitory Activity
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
WO2002078701A1 (en) 2001-03-30 2002-10-10 Smithkline Beecham Corporation Use of pyrazolopyridines as therapeutic compounds
WO2002078700A1 (en) 2001-03-30 2002-10-10 Smithkline Beecham Corporation Pyralopyridines, process for their preparation and use as therapteutic compounds
WO2002088124A2 (en) 2001-04-27 2002-11-07 Smithkline Beecham Corporation Pyrazolo'1,5-a!pyridine derivatives
CZ294535B6 (en) 2001-08-02 2005-01-12 Ústav Experimentální Botaniky Avčr Heterocyclic compounds based on N6-substituted adenine, processes of their preparation, their use in the preparation of medicaments, cosmetic compositions and growth regulators, as well as pharmaceutical preparations, cosmetic compositions and growth regulators in which these compounds are comprised
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
US8124625B2 (en) 2001-09-14 2012-02-28 Shionogi & Co., Ltd. Method of enhancing the expression of apolipoprotein AI using olefin derivatives
MXPA04002243A (en) 2001-09-19 2004-06-29 Aventis Pharma Sa Chemical compounds.
BR0212829A (en) 2001-09-26 2004-08-03 Bayer Pharmaceuticals Corp 1,8-Naphthyridine derivatives and their use to treat diabetes and related disorders
DE60228103D1 (en) 2001-10-02 2008-09-18 Smithkline Beecham Corp CHEMICAL COMPOUNDS
ATE335490T1 (en) 2001-10-30 2006-09-15 Novartis Pharma Gmbh STAUROSPORINE DERIVATIVES AS INHIBITORS OF FLT3 RECEPTOR TYROSINE KINASE ACTION
US7262164B2 (en) 2001-11-09 2007-08-28 Enzon, Inc. Polymeric thiol-linked prodrugs employing benzyl elimination systems
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
WO2003049678A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
JP4597519B2 (en) 2001-12-06 2010-12-15 メルク・シャープ・エンド・ドーム・コーポレイション Mitotic kinesin inhibitor
TW200301135A (en) 2001-12-27 2003-07-01 Otsuka Maryland Res Inst Inc Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor
WO2003068750A1 (en) 2002-02-13 2003-08-21 Takeda Chemical Industries, Ltd. Jnk inhibitor
US20050049267A1 (en) 2002-03-01 2005-03-03 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
ES2291628T3 (en) 2002-04-03 2008-03-01 Bristol-Myers Squibb Company THYROPHENE BASED THYMPHENE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH COMPOUNDS.
KR20050006221A (en) 2002-05-06 2005-01-15 제네랩스 테크놀로지스, 인코포레이티드 Nucleoside derivatives for treating hepatitis c virus infection
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
ATE404537T1 (en) 2002-08-13 2008-08-15 Shionogi & Co HETEROCYCLIC COMPOUNDS HAVING HIV-INTEGRASE-INHIBITING EFFECT
JP4190232B2 (en) 2002-08-26 2008-12-03 富士通株式会社 How to perform mechanical polishing
MXPA05003193A (en) 2002-09-27 2005-06-08 Sumitomo Pharma Novel adenine compound and use thereof.
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
EA013811B1 (en) 2002-11-21 2010-08-30 Новартис Вэксинес Энд Дайэгностикс, Инк. 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer
EP1568688B1 (en) 2002-11-25 2011-08-31 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for respiratory disease containing 4-hydroxypiperidine derivative as active ingredient
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
JP4500689B2 (en) 2002-12-26 2010-07-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 Selective estrogen receptor modulator
CZ294538B6 (en) 2002-12-30 2005-01-12 Ústav Experimentální Botaniky Akademie Vědčeské Re Substituting derivatives of N6-benzyladenosine, process of their preparation, their use in the preparation of medicaments, cosmetic compositions and growth regulators, as well as pharmaceutical preparations, cosmetic compositions and growth regulators in which these compounds are comprised
RU2233842C1 (en) 2003-01-13 2004-08-10 Петров Владимир Иванович Derivatives of purine eliciting antiviral activity
PE20050068A1 (en) 2003-02-06 2005-03-11 Novartis Ag 2-CYANOPYRROLOPYRIMIDINES AS INHIBITORS OF CATEPSIN S
GB0304640D0 (en) 2003-02-28 2003-04-02 Novartis Ag Organic compounds
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
SE0300908D0 (en) 2003-03-31 2003-03-31 Astrazeneca Ab Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
CA2524376A1 (en) 2003-05-05 2004-12-16 Neurogen Corporation Substituted imidazolopyrazine and triazolopyrazyne derivatives: gabaa receptor ligands
MXPA05013142A (en) 2003-06-20 2006-03-17 Chiron Corp Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents.
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
JP4570015B2 (en) 2003-07-14 2010-10-27 クミアイ化学工業株式会社 2-Isoxazoline derivatives and herbicides containing them as active ingredients
US20050124637A1 (en) 2003-08-15 2005-06-09 Irm Llc Compounds and compositions as inhibitors of receptor tyrosine kinase activity
WO2005028434A2 (en) 2003-09-18 2005-03-31 Conforma Therapeutics Corporation Novel heterocyclic compounds as hsp90-inhibitors
CA2539853C (en) 2003-09-23 2011-04-19 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
AR045944A1 (en) 2003-09-24 2005-11-16 Novartis Ag ISOQUINOLINE DERIVATIVES 1.4-DISPOSED
JP2007520559A (en) 2004-02-03 2007-07-26 アボット・ラボラトリーズ Aminobenzoxazoles as therapeutic agents
JPWO2005077948A1 (en) 2004-02-16 2008-01-10 第一製薬株式会社 Antifungal heterocyclic compounds
CN1560035A (en) 2004-03-12 2005-01-05 沈阳药科大学 5-hydroxylic indole-3-carboxylic ester kind derivantion
WO2005091857A2 (en) 2004-03-12 2005-10-06 Bayer Pharmaceuticals Corporation 1,6-naphthyridine and 1,8-naphthyridine derivatives and their use to treat diabetes and related disorders
US20070225303A1 (en) 2004-03-26 2007-09-27 Haruhisa Ogita 8-Oxoadenine Compound
EP1740587A4 (en) 2004-04-02 2009-07-15 Adenosine Therapeutics Llc Selective antagonists of a-2a- adenosine receptors
ES2605792T3 (en) 2004-05-13 2017-03-16 Icos Corporation Quinazolinone used as a human phosphatidylinositol 3-kinase delta inhibitor
US20060074102A1 (en) 2004-05-14 2006-04-06 Kevin Cusack Kinase inhibitors as therapeutic agents
EP1773830A1 (en) 2004-07-22 2007-04-18 AstraZeneca AB Fused pyrimidones useful in the treatment and the prevention of cancer
KR20070046176A (en) 2004-08-18 2007-05-02 아스트라제네카 아베 Enantiomers of selected fused pyrimidones and uses in the treatment and prevention of cancer
DE102004044221A1 (en) 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 3-methyl-7-butynyl xanthines, their preparation and their use as pharmaceuticals
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
MX2007004699A (en) 2004-10-19 2007-06-14 Novartis Vaccines & Diagnostic Indole and benzimidazole derivatives.
EP1807417A2 (en) 2004-11-04 2007-07-18 Neurogen Corporation Pyrazolylmethyl heteroaryl derivatives
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
WO2006056399A2 (en) 2004-11-24 2006-06-01 Novartis Ag Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
AU2006214190A1 (en) 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
US7799795B2 (en) 2005-06-27 2010-09-21 Amgen Inc. Aryl nitrile compounds and compositions and their uses in treating inflammatory and related disorders
FR2889192A1 (en) 2005-07-27 2007-02-02 Cytomics Systems Sa ANTIFUNGAL COMPOUNDS, COMPOSITIONS CONTAINING THESE COMPOUNDS, AND USES THEREOF
EP1924265A4 (en) 2005-08-16 2010-06-02 Genzyme Corp Chemokine receptor binding compounds
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
JPWO2007034817A1 (en) 2005-09-22 2009-03-26 大日本住友製薬株式会社 New adenine compounds
GB0520657D0 (en) * 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
NZ592990A (en) 2005-11-01 2013-01-25 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
EP1783114A1 (en) 2005-11-03 2007-05-09 Novartis AG N-(hetero)aryl indole derivatives as pesticides
US7557213B2 (en) 2005-11-10 2009-07-07 Chemocentryx, Inc. Substituted quinolones and methods of use
CN103214483B (en) 2005-12-13 2014-12-17 因塞特公司 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
EP1984375A2 (en) 2006-01-25 2008-10-29 Smithkline Beecham Corporation Chemical compounds
PE20071025A1 (en) 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp TRISUSTITUTED AMINE COMPOUND
PE20070978A1 (en) 2006-02-14 2007-11-15 Novartis Ag HETEROCICLIC COMPOUNDS AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASES (PI3Ks)
WO2007102392A1 (en) 2006-03-03 2007-09-13 Shionogi & Co., Ltd. Mmp-13-selective inhibitor
EA200870385A1 (en) 2006-03-29 2009-04-28 Фолдркс Фармасьютикалз, Инк. INHIBITION OF TOXICITY ALPHA-SINUCLEINE
CA2647391C (en) * 2006-04-04 2015-12-29 The Regents Of The University Of California Kinase antagonists
DE102006029074A1 (en) * 2006-06-22 2007-12-27 Friedrich-Schiller-Universität Jena 4-Amino-3-arylamino-6-arylpyrazolo [3,4-d] pyrimidine derivatives, process for their preparation and their use as antiviral agents
EP2037905B1 (en) 2006-06-23 2013-05-01 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
EP2044086A2 (en) 2006-06-30 2009-04-08 Janssen Pharmaceutica N.V. Thiazolopyrimidine modulators of trpv1
US20080009508A1 (en) 2006-07-10 2008-01-10 Lucie Szucova 6,9-Disubstituted Purine Derivatives And Their Use For Treating Skin
US20100035756A1 (en) 2006-07-12 2010-02-11 Syngenta Limited Triazolophyridine derivatives as herbicides
NZ575274A (en) 2006-08-08 2010-11-26 Chugai Pharmaceutical Co Ltd Pyrimidine derivative as pi3k inhibitor and use thereof
CN103641829A (en) 2006-08-30 2014-03-19 塞尔佐姆有限公司 Triazole derivatives as kinase inhibitors
WO2008032033A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
EP1972631A1 (en) 2007-03-23 2008-09-24 Novartis AG Imidazopyridazines as PI3K lipid kinase inhibitors
WO2008055013A2 (en) 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase
CA2669399A1 (en) 2006-11-13 2008-05-29 Eli Lilly & Co. Thienopyrimidinones for treatment of inflammatory disorders and cancers
AU2007323725B2 (en) 2006-11-22 2014-02-20 Incyte Holdings Corporation Imidazotriazines and imidazopyrimidines as kinase inhibitors
JP2010513495A (en) 2006-12-20 2010-04-30 シェーリング コーポレイション Novel JNK inhibitor
CN101589046B (en) 2006-12-29 2011-09-21 弗·哈夫曼-拉罗切有限公司 Azaspiro derivatives
US20080194616A1 (en) 2007-02-05 2008-08-14 Xenon Pharmaceuticals Inc. Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions
MX2009008439A (en) 2007-02-12 2009-08-13 Intermune Inc Novel inhibitors hepatitis c virus replication.
PE20081887A1 (en) 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co NEW ADENINE COMPOUND
US20080233127A1 (en) 2007-03-21 2008-09-25 Wyeth Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
UA98955C2 (en) 2007-03-23 2012-07-10 Амген Инк. Heterocyclic compounds and their uses
MX2009009913A (en) 2007-03-23 2009-10-16 Amgen Inc Derivatives of quinoline or benzopyrazine and their uses for the treatment of (inter alia) inflammatory diseases, autoimmune diseases or various kinds of cancer.
US8039505B2 (en) 2007-04-11 2011-10-18 University Of Utah Research Foundation Compounds for modulating T-cells
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
JP2010531304A (en) 2007-06-18 2010-09-24 ユニバーシティ オブ ルイビル リサーチ ファウンデーション、インコーポレイテッド PFKFB3 inhibitor family with antineoplastic activity
CA2691444C (en) 2007-06-29 2016-06-14 Gilead Sciences, Inc. Purine derivatives and their use as modulators of toll-like receptor 7
WO2009042294A2 (en) 2007-08-10 2009-04-02 Burnham Institute For Medical Research Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof
TW200916447A (en) 2007-08-29 2009-04-16 Methylgene Inc Sirtuin inhibitors
JP2009076865A (en) 2007-08-29 2009-04-09 Fujifilm Corp Organic electroluminescence device
WO2009034386A1 (en) 2007-09-13 2009-03-19 Astrazeneca Ab Derivatives of adenine and 8-aza-adenine and uses thereof-796
JP2009080233A (en) 2007-09-26 2009-04-16 Kyocera Mita Corp Electrophotographic photoreceptor
CZ300774B6 (en) 2007-10-05 2009-08-05 Univerzita Palackého Substituted 6-(alkylbenzylamino)purine derivatives for use as cytokinin receptor antagonists and compositions in which these compounds are comprised
AU2008323694A1 (en) 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
WO2009063235A1 (en) 2007-11-13 2009-05-22 Astrazeneca Ab Derivatives of 1,9-dihydro-6h-purin-6-one and uses thereof-018
JP2009120686A (en) 2007-11-14 2009-06-04 Toyo Ink Mfg Co Ltd Photopolymerization initiator, polymerizable composition, and method for producing polymer
AU2008343813B2 (en) 2007-12-19 2012-04-12 Amgen Inc. Inhibitors of PI3 kinase
WO2009081105A2 (en) 2007-12-21 2009-07-02 Ucb Pharma S.A. Quinoxaline and quinoline derivatives as kinase inhibitors
CN101945871A (en) 2007-12-21 2011-01-12 惠氏有限责任公司 Imidazo [1,2-a] pyridine compounds
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US7960397B2 (en) 2007-12-28 2011-06-14 Institute Of Experimental Botany, Academy Of Sciences Of The Czech Republic 6,9-disubstituted purine derivatives and their use as cosmetics and cosmetic compositions
US8410098B2 (en) 2007-12-28 2013-04-02 Topharman Shanghai Co., Ltd. N-{1-[3-(2-ethoxy-5-(4-ethylpiperazinyl)sulfonylphenyl)-4,5-dihydro-5-OXO-1,2,4-triazin-6-yl]ethyl}butyramide, the preparation method and use thereof
US8193182B2 (en) * 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
AU2009211004C1 (en) 2008-01-11 2013-08-01 Natco Pharma Limited Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents
US9089572B2 (en) 2008-01-17 2015-07-28 California Institute Of Technology Inhibitors of p97
ES2494365T3 (en) 2008-01-30 2014-09-15 Genentech, Inc. Pyrazolopyrimidine compounds that inhibit PI3K and methods of use
EP2444403A1 (en) 2008-04-18 2012-04-25 Shionogi Co., Ltd. Heterocyclic compound having inhibitory activity on PI3K
US8119647B2 (en) 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
WO2009140215A2 (en) 2008-05-11 2009-11-19 Geraghty, Erin Method for treating drug-resistant bacterial and other infections with clioquinol, phanquinone, and related compounds
EP2300005A4 (en) 2008-05-28 2011-07-13 Us Of America As Represented By The Secretary Of The Army On Behalf Of U S Army Medical Res And Mate Small molecule inhibitors of botulinum neurotoxins
KR20110026481A (en) 2008-06-20 2011-03-15 메타볼렉스, 인코포레이티드 Aryl gpr119 agonists and uses thereof
US8026271B2 (en) 2008-07-11 2011-09-27 National Health Research Institutes Formulations of indol-3-yl-2-oxoacetamide compounds
WO2010018458A2 (en) 2008-08-12 2010-02-18 Crystalgenomics, Inc. Phenol derivatives and methods of use thereof
US8703778B2 (en) * 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
CN104042618B (en) 2008-11-13 2018-02-16 吉利德卡利斯托加公司 The treatment of malignant hematologic disease
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
AU2009330821B2 (en) 2008-12-24 2015-06-11 Bial - Portela & Ca, S.A. Pharmaceutical compounds
EP2387575B1 (en) 2009-01-15 2013-09-04 Anvyl, LLC Alpha7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof
ES2598358T3 (en) 2009-02-13 2017-01-27 Ucb Pharma, S.A. Quinoline derivatives as PI3K kinase inhibitors
EP2414044A1 (en) 2009-03-31 2012-02-08 ArQule, Inc. Substituted indolo-piperidine compounds
WO2010118367A2 (en) 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
EA201101507A1 (en) 2009-04-20 2012-05-30 Гилеад Калистога Ллс. METHODS OF TREATMENT OF SOLID TUMORS
WO2010127208A1 (en) 2009-04-30 2010-11-04 Forest Laboratories Holdings Limited Inhibitors of acetyl-coa carboxylase
JP5789252B2 (en) 2009-05-07 2015-10-07 インテリカイン， エルエルシー Heterocyclic compounds and uses thereof
BRPI1012159B1 (en) 2009-05-22 2022-01-25 Incyte Holdings Corporation Compounds derived from n-(hetero)aryl-pyrrolidine of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors, compositions pharmaceuticals comprising said compounds and uses thereof
AU2010266064A1 (en) 2009-06-25 2012-01-19 Amgen Inc. 4H - pyrido [1, 2 - a] pyrimidin - 4 - one derivatives as PI3 K inhibitors
UY32743A (en) * 2009-06-25 2010-12-31 Amgen Inc HETEROCYCLIC COMPOUNDS AND THEIR USES
PL2448582T3 (en) 2009-06-29 2017-09-29 Agios Pharmaceuticals, Inc. Quinoline-8-sulfonamide derivatives having an anticancer activity
FR2947269B1 (en) 2009-06-29 2013-01-18 Sanofi Aventis NEW ANTICANCER COMPOUNDS
AR077252A1 (en) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc ESPIROOXINDOL COMPOUND ENANTIOMERS AND THEIR USES AS THERAPEUTIC AGENTS
PL2448938T3 (en) 2009-06-29 2014-11-28 Incyte Holdings Corp Pyrimidinones as pi3k inhibitors
EP2456443A1 (en) 2009-07-21 2012-05-30 Gilead Calistoga LLC Treatment of liver disorders with pi3k inhibitors
DK2470546T3 (en) 2009-08-28 2013-10-14 Takeda Pharmaceutical HEXAHYDROOXAZINOPTERIDIN compounds for use as mTOR INHIBITORS
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EA022120B1 (en) 2009-10-20 2015-11-30 Целльзом Лимитид Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors
ES2644286T3 (en) 2009-10-22 2017-11-28 Gilead Sciences, Inc. Purine or deazapurine derivatives useful for the treatment of (among others) viral infections
AP2012006294A0 (en) 2009-11-05 2012-06-30 Rhizen Pharmaceuticals Sa Novel kinase modulators.
DK2499139T3 (en) 2009-11-10 2014-01-27 Pfizer N1 PYRAZOLOSPIROKETON-acetyl-CoA carboxylase
EP2499126B1 (en) 2009-11-12 2015-01-07 UCB Pharma, S.A. Fused bicyclic pyridine and pyrazine derivatives as kinase inhibitors
WO2011058111A1 (en) 2009-11-12 2011-05-19 Ucb Pharma S.A. Aminopurine derivatives as kinase inhibitors
CN102812033B (en) 2009-12-10 2015-11-25 中国医学科学院药物研究所 N6-substituted adenosines derivative and N6-substituted adenines derivative and uses thereof
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
WO2011075630A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors
EP2513109A1 (en) 2009-12-18 2012-10-24 Amgen Inc. Heterocyclic compounds and their uses
PE20121505A1 (en) * 2009-12-23 2012-11-05 Medicis Pharmaceutical Corp AMINOALKYLPYRIMIDINE DERIVATIVES AS ANTAGONISTS OF THE HISTAMINE H4 RECEPTOR
JP2011136925A (en) 2009-12-28 2011-07-14 Dainippon Sumitomo Pharma Co Ltd Nitrogen-containing bicyclic compound
EP2521452B1 (en) 2010-01-07 2014-12-24 Dow AgroSciences LLC THIAZOLO[5,4-d]PYRIMIDINES AND THEIR USE AS AGROCHEMICALS
US8633183B2 (en) 2010-01-26 2014-01-21 Boehringer Ingelheim International Gmbh 5-alkynyl-pyrimidines
KR102283091B1 (en) 2010-03-10 2021-07-30 인사이트 홀딩스 코포레이션 Piperidin-4-yl azetidine derivatives as jak1 inhibitors
CN102802632A (en) 2010-03-22 2012-11-28 格兰马克药品股份有限公司 Pharmaceutical composition comprising a pyrimidineone derivative
UY33304A (en) 2010-04-02 2011-10-31 Amgen Inc HETEROCYCLIC COMPOUNDS AND THEIR USES
WO2011130342A1 (en) 2010-04-14 2011-10-20 Incyte Corporation FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
EP2571357B1 (en) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US20110306622A1 (en) 2010-06-11 2011-12-15 Calitoga Pharmaceuticals, Inc. Methods of treating hematological disorders with quinazolinone compounds in selected subjects
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
WO2012003274A1 (en) 2010-07-01 2012-01-05 Amgen Inc. Heterocyclic compounds and their use as inhibitors of pi3k activity
US8759371B2 (en) 2010-07-01 2014-06-24 Amgen Inc. Heterocyclic compounds and their uses
MX2012015134A (en) 2010-07-02 2013-05-06 Amgen Inc Heterocyclic compounds and their use as inhibitors of pi3k activity.
CA2812467A1 (en) 2010-09-24 2012-03-29 Gilead Calistoga Llc Atropisomers of pi3k-inhibiting compounds
US20140031355A1 (en) 2010-11-04 2014-01-30 Amgen Inc. Heterocyclic compounds and their uses
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2640715A1 (en) 2010-11-17 2013-09-25 Amgen Inc. Quinoline derivatives as pik3 inhibitors
AR083933A1 (en) 2010-11-19 2013-04-10 Incyte Corp PIRROLOPIRIDINE AND PIRROLOPIRIMIDINE DERIVATIVES REPLACED WITH CYCLOBUTILO AS JAK INHIBITORS
JP5917544B2 (en) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Heterocyclic substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
EP2651405A2 (en) 2010-12-14 2013-10-23 Electrophoretics Limited Casein kinase 1 (ck1 ) inhibitors
JP5961187B2 (en) 2010-12-20 2016-08-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ N- (1- (substituted phenyl) ethyl) -9H-purin-6-amine as a PI3K inhibitor
EP2655342A1 (en) 2010-12-23 2013-10-30 Amgen Inc. Heterocyclic compounds and their uses
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US9249087B2 (en) 2011-02-01 2016-02-02 The Board Of Trustees Of The University Of Illinois HDAC inhibitors and therapeutic methods using the same
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
CN103797010B (en) 2011-06-20 2016-02-24 因塞特控股公司 As the azetidinyl phenyl of JAK inhibitor, pyridyl or pyrazinyl carboxamides derivatives
CN103930422A (en) 2011-07-19 2014-07-16 无限药品股份有限公司 Heterocyclic compounds and uses thereof
TW201313721A (en) 2011-08-18 2013-04-01 Incyte Corp Cyclohexyl azetidine derivatives as JAK inhibitors
HUE030869T2 (en) 2011-09-02 2017-06-28 Incyte Holdings Corp Heterocyclylamines as pi3k inhibitors
CA2850763A1 (en) 2011-10-04 2013-04-11 Gilead Calistoga Llc Novel quinoxaline inhibitors of pi3k
AR090548A1 (en) 2012-04-02 2014-11-19 Incyte Corp BICYCLIC AZAHETEROCICLOBENCILAMINS AS PI3K INHIBITORS
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
SG10201703533VA (en) 2012-11-01 2017-06-29 Incyte Corp Tricyclic fused thiophene derivatives as jak inhibitors
TWI736135B (en) 2013-03-01 2021-08-11 美商英塞特控股公司 USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS
KR102311329B1 (en) 2013-03-15 2021-10-14 얀센 파마슈티카 엔.브이. Processes and intermediates for preparing a medicament
HUE043573T2 (en) 2013-05-17 2019-08-28 Incyte Corp Bipyrazole salt as jak inhibitor
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
TWI770525B (en) 2014-12-30 2022-07-11 美商瓦洛健康公司 Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors
AU2016222556B2 (en) 2015-02-27 2020-08-27 Incyte Holdings Corporation Salts of Pl3K inhibitor and processes for their preparation
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183062A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2019232188A1 (en) 2018-06-01 2019-12-05 Incyte Corporation Dosing regimen for the treatment of pi3k related disorders

Also Published As

Publication number Publication date
KR20140082680A (en) 2014-07-02
KR102371532B1 (en) 2022-03-07
CO6910199A2 (en) 2014-03-31
PT2751109T (en) 2017-03-06
US20130059835A1 (en) 2013-03-07
TW201833115A (en) 2018-09-16
EA028890B1 (en) 2018-01-31
PE20181272A1 (en) 2018-08-03
KR20190045381A (en) 2019-05-02
DK2751109T3 (en) 2017-01-23
IL231239A (en) 2017-05-29
JP2023184724A (en) 2023-12-28
KR101982475B1 (en) 2019-05-27
IL299533A (en) 2023-02-01
TW201942119A (en) 2019-11-01
MX360262B (en) 2018-10-26
US20230121440A1 (en) 2023-04-20
EP2751109B1 (en) 2016-11-30
KR20200084905A (en) 2020-07-13
US20190134040A1 (en) 2019-05-09
HRP20170285T1 (en) 2017-04-21
EP3196202B1 (en) 2019-02-27
HUE043703T2 (en) 2019-09-30
ME02595B (en) 2017-06-20
IL252184B (en) 2019-01-31
CR20140111A (en) 2014-06-10
BR122019020716B1 (en) 2021-02-17
IL257576B (en) 2020-07-30
NZ717505A (en) 2017-10-27
CN106986867B (en) 2019-06-28
JP2014527959A (en) 2014-10-23
TWI619714B (en) 2018-04-01
WO2013033569A1 (en) 2013-03-07
CR20180293A (en) 2018-09-19
LT3513793T (en) 2021-06-10
HUE053953T2 (en) 2021-08-30
US9730939B2 (en) 2017-08-15
KR20210054022A (en) 2021-05-12
AU2017206260B2 (en) 2019-02-14
NZ769326A (en) 2022-07-01
JP6263591B2 (en) 2018-01-17
HRP20190824T1 (en) 2019-07-12
AU2022291574A1 (en) 2023-02-02
PT3196202T (en) 2019-05-31
IL284539B2 (en) 2023-06-01
EA033646B1 (en) 2019-11-13
CA2846652A1 (en) 2013-03-07
NZ751428A (en) 2020-11-27
TWI648277B (en) 2019-01-21
RS55737B1 (en) 2017-07-31
AU2021200266A1 (en) 2021-03-18
TW201313715A (en) 2013-04-01
US20160022685A1 (en) 2016-01-28
JP6067709B2 (en) 2017-01-25
KR20190122801A (en) 2019-10-30
ME03397B (en) 2020-01-20
TWI543980B (en) 2016-08-01
JP7384891B2 (en) 2023-11-21
ECSP14013274A (en) 2014-04-30
KR20230038593A (en) 2023-03-20
RS58817B1 (en) 2019-07-31
AU2012301721A1 (en) 2014-03-20
IL273079A (en) 2020-04-30
JP2019194266A (en) 2019-11-07
TWI673272B (en) 2019-10-01
CN104024253A (en) 2014-09-03
BR112014004971A2 (en) 2017-03-21
EP3888657A1 (en) 2021-10-06
CA2846652C (en) 2019-11-05
SG10201601589QA (en) 2016-04-28
EA201791929A1 (en) 2018-04-30
KR20220035265A (en) 2022-03-21
US9199982B2 (en) 2015-12-01
US20200323858A1 (en) 2020-10-15
NZ735378A (en) 2019-04-26
LT3196202T (en) 2019-07-10
DK3513793T3 (en) 2021-04-26
BR112014004971B1 (en) 2021-02-09
EP3196202A1 (en) 2017-07-26
IL252184A0 (en) 2017-07-31
NZ621991A (en) 2016-07-29
PL2751109T3 (en) 2017-06-30
TW202118765A (en) 2021-05-16
US20190298724A1 (en) 2019-10-03
IL257576A (en) 2018-04-30
PT3513793T (en) 2021-05-10
HUE030869T2 (en) 2017-06-28
SI3513793T1 (en) 2021-07-30
ES2616477T3 (en) 2017-06-13
HRP20210627T1 (en) 2021-05-28
JP6266743B2 (en) 2018-01-24
MY179332A (en) 2020-11-04
ZA201904877B (en) 2022-11-30
DK3196202T3 (en) 2019-05-13
AU2019201423B2 (en) 2020-10-22
KR102131612B1 (en) 2020-07-08
US20160024117A1 (en) 2016-01-28
TWI717002B (en) 2021-01-21
KR102507287B1 (en) 2023-03-07
CY1121651T1 (en) 2020-07-31
AR087760A1 (en) 2014-04-16
AU2019201423A1 (en) 2019-03-21
PH12017501766A1 (en) 2018-10-29
IL231239A0 (en) 2014-04-30
JP2017019851A (en) 2017-01-26
JP6574039B2 (en) 2019-09-11
JP6427257B2 (en) 2018-11-21
AU2021200266B2 (en) 2022-09-29
SI2751109T1 (en) 2017-03-31
PE20141726A1 (en) 2014-11-26
IL273079B (en) 2021-07-29
PL3513793T3 (en) 2021-09-20
AU2017206260A1 (en) 2017-08-10
US11433071B2 (en) 2022-09-06
PH12017501766B1 (en) 2018-10-29
US10646492B2 (en) 2020-05-12
US10376513B2 (en) 2019-08-13
MX2020004502A (en) 2022-01-20
US10092570B2 (en) 2018-10-09
ES2873001T3 (en) 2021-11-03
JP2019011375A (en) 2019-01-24
EP3513793B1 (en) 2021-03-10
CY1118679T1 (en) 2017-07-12
AU2012301721B2 (en) 2017-08-10
TW201639842A (en) 2016-11-16
EP3513793A1 (en) 2019-07-24
CN106986867A (en) 2017-07-28
TW201917128A (en) 2019-05-01
EP2751109A1 (en) 2014-07-09
ES2722524T3 (en) 2019-08-13
LT2751109T (en) 2017-02-27
JP2018044008A (en) 2018-03-22
CL2014000517A1 (en) 2014-08-22
SG10201912484RA (en) 2020-02-27
BR112014004971A8 (en) 2019-11-05
NZ765458A (en) 2021-10-29
US20170340641A1 (en) 2017-11-30
SMT201700111B (en) 2017-03-08
US20240216377A1 (en) 2024-07-04
US9707233B2 (en) 2017-07-18
HK1199644A1 (en) 2015-07-10
KR102030609B1 (en) 2019-10-11
JP2017052805A (en) 2017-03-16
SI3196202T1 (en) 2019-05-31
IL284539A (en) 2021-08-31
JP2022034029A (en) 2022-03-02
KR102249236B1 (en) 2021-05-10
US11819505B2 (en) 2023-11-21
PH12019502246A1 (en) 2021-02-22
RS61761B1 (en) 2021-05-31
JP7038685B2 (en) 2022-03-18
CY1124168T1 (en) 2022-05-27
TWI765515B (en) 2022-05-21
MX2014002360A (en) 2014-04-25
PL3196202T3 (en) 2019-09-30
EA201490541A1 (en) 2014-08-29

Similar Documents

Publication Publication Date Title
IL273079B (en) Heterocyclylamines as pi3k inhibitors
HK1195552A1 (en) Pyrrolotriazinone derivatives as pi3k inhibitors pi3k
EP2683693A4 (en) Rorgammat inhibitors
HK1211027A1 (en) Pyrrolotriazinone derivatives as pi3k inhibitors pi3k
SG10202003090VA (en) PI3K δ INHIBITOR
IL228103A0 (en) Amino-quinolines as kinase inhibitors
EP2685992A4 (en) Amino-quinolines as kinase inhibitors
GB201120474D0 (en) Inhibitors
GB201104399D0 (en) Novel inhibitors